Group 1 - Monteverde & Associates PC is investigating Alimera Sciences, Inc. regarding its proposed merger with ANI Pharmaceuticals, Inc. [1] - Under the merger agreement, Alimera Sciences shareholders will receive $5.50 per share and one contingent value right, which could provide up to $0.50 per share based on achieving specific net revenue targets in 2026 and 2027 [1] - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report, highlighting its successful track record in recovering money for shareholders [1][3] Group 2 - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [3] - The firm encourages shareholders with concerns to contact them for additional information free of charge [3] - The firm emphasizes that no company, director, or officer is above the law, reinforcing its commitment to shareholder rights [3]
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.